Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Debt (2020 - 2025)

Gain Therapeutics has reported Total Debt over the past 6 years, most recently at $424342.0 for Q3 2025.

  • Quarterly results put Total Debt at $424342.0 for Q3 2025, down 14.17% from a year ago — trailing twelve months through Sep 2025 was $424342.0 (down 14.17% YoY), and the annual figure for FY2024 was $438504.0, down 22.78%.
  • Total Debt for Q3 2025 was $424342.0 at Gain Therapeutics, down from $451467.0 in the prior quarter.
  • Over the last five years, Total Debt for GANX hit a ceiling of $722542.0 in Q1 2021 and a floor of $424342.0 in Q3 2025.
  • Median Total Debt over the past 5 years was $578274.0 (2023), compared with a mean of $568748.8.
  • Biggest five-year swings in Total Debt: dropped 5.89% in 2023 and later fell 22.78% in 2024.
  • Gain Therapeutics' Total Debt stood at $694294.0 in 2021, then fell by 13.09% to $603393.0 in 2022, then dropped by 5.89% to $567850.0 in 2023, then dropped by 22.78% to $438504.0 in 2024, then dropped by 3.23% to $424342.0 in 2025.
  • The last three reported values for Total Debt were $424342.0 (Q3 2025), $451467.0 (Q2 2025), and $427597.0 (Q1 2025) per Business Quant data.